biotech / news / / MarketScreener
Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab.
The BRUIN CLL-322 trial showed pirtobrutinib plus venetoclax and rituximab improved progression-free survival.
KEY POINTS
- Improvement in progression-free survival was consistent regardless of prior covalent BTK inhibitor treatment.
- Overall survival data are not mature but currently trend in favor of the pirtobrutinib combination.
- Safety profiles and discontinuation rates were similar between the pirtobrutinib combination and control arms.
- Lilly plans to submit these results for regulatory label expansion later this year.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →